Structure's lead candidate, aleniglipron, an oral GLP-1R agonist, shows potential in obesity treatment, with significant Phase 2 data expected in Q4 2025. Despite a crowded GLP-1 drug development ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Glucagon-like peptide-1 (GLP-1) was first discovered in the 1980s as a regulator of glucose levels. Further research led to the creation of a stabilized GLP-1RA called semaglutide, the active ...

Experts across healthcare debunk 15 common myths about GLP-1 medications—covering everything from access and cost to ...

Two undergraduate medicine students at University of Galway have led a major study examining how cardioprotective ...

GLP-1 agonists may lead to increased nausea and vomiting in the early postoperative period after total hip arthroplasty, ...

and GLP-1 agonists such as semaglutide (in people with both HFpEF and obesity). These drugs help people lose weight and have also been shown to reduce hospitalization for heart failure.

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

SAN DIEGO — Stopping GLP-1 receptor agonists 14 days prior to total hip or knee arthroplasty may reduce several key risk factors associated with anesthesia complications, according to results ...

and GLP-1 agonists such as semaglutide (in people with both HFpEF and obesity). These drugs help people lose weight and have also been shown to reduce hospitalization for heart failure.

and GLP-1 agonists such as semaglutide (in people with both HFpEF and obesity). These drugs help people lose weight and have also been shown to reduce hospitalization for heart failure.

While furosemide and other diuretics can help with symptoms, the drugs that have had a very significant impact on the management of HFpEF have been drugs that were initially used for diabetes, SGLT2 ...